Galectin Therapeutics (GALT) Adds to Recent Speculative Gains

September 22, 2016 8:19 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Galectin Therapeutics (NASDAQ: GALT) adds to recent gains amid NASH stock takeover speculation following Allergen's (NYSE: AGN) recent takeover of Tobira (NASDAQ: TBRA) at a huge premium and ahead of top line results from a Phase 2 clinical trial due by the end of the month.

Shares of GALT are up 10% in pre-open trade after rising 35% yesterday.

A HC Wainwright analyst told StreetInsider on Tuesday that he sees GALT as having the best read through from TBRA.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Momentum Movers, Trader Talk

Related Entities

Pre Market Movers, H.C. Wainwright

Add Your Comment